Anuh Pharma Limited (ANUHPHR) AI Stock Analysis

• Market Cap: ₹7.72B
• Dividend Yield: 1.92%
• Average Volume (3M): 6.00K
• Price to Earnings (P/E): 19.9
• Beta (1Y): 0.73
• Revenue Growth: 14.09%
• EPS Growth: -34.41%
• Country: IN
• Employees: 295
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.76
• Shares Outstanding: 100,224,000
• 10 Day Avg. Volume: 6,374
• 30 Day Avg. Volume: 5,996
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 62 Neutral
• Price Target: ₹82.00 ▲(5.77% Upside)

Anuh Pharma Limited's overall stock score reflects solid financial health with consistent revenue growth and a strong balance sheet. However, the stock is currently in a bearish trend, trading below key moving averages. The valuation is fair, with a reasonable P/E ratio and moderate dividend yield. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Revenue Growth

Consistent revenue growth, even if slower, indicates sustained demand for products and a stable market presence, supporting long-term business viability.

Balance Sheet Health

A low debt-to-equity ratio suggests minimal financial risk and strong financial health, providing flexibility for future investments and growth opportunities.

Cash Flow Generation

Strong free cash flow growth enhances the company's ability to reinvest in operations, pay down debt, or return capital to shareholders, supporting long-term sustainability.

Negative Factors

Profit Margin Pressure

Decreasing net profit margins indicate rising costs or pricing pressures, which could affect profitability and limit reinvestment capacity over time.

Declining ROE

A declining ROE suggests reduced efficiency in generating profits from equity, potentially impacting investor confidence and long-term growth prospects.

Operational Efficiency Challenges

Declining EBIT and EBITDA margins suggest operational inefficiencies, which may hinder the company's ability to maintain competitive pricing and profitability.

Anuh Pharma Limited Business Overview & Revenue Model

Company Description

Anuh Pharma Limited engages in the manufacture and sale of bulk drugs and chemicals in India. It offers active pharmaceutical ingredients, including macrolides, anti-TB, anti-bacterial, anti-asthmatics, anti-diabetics, intermediates, expectorant, quinolones, anti-malarial, anti-gout, anti-biotic, anti-platelet, and antihistamines; and corticosteroids, including anti-inflammatory, immunosuppressant, anti-pruritic, anti-mitotic. The company also develops products, such as coagulants, gastrointestinal, anti convulsants, and cholesterol drugs. It also exports its products. The company was incorporated in 1960 and is headquartered in Mumbai, India.

How the Company Makes Money

Anuh Pharma Limited generates revenue through multiple key streams, primarily from the sale of its pharmaceutical products, which include prescription medications and over-the-counter drugs. The company benefits from both domestic and international markets, leveraging its manufacturing capabilities to produce generics that appeal to cost-sensitive consumers and healthcare systems. Additionally, Anuh Pharma may engage in strategic partnerships with other pharmaceutical companies for co-development and distribution agreements, which can provide significant revenue-sharing opportunities. The company also invests in research and development to create new therapies, which can lead to lucrative patent-protected products, further enhancing its earnings potential.

Anuh Pharma Limited Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.62B	6.47B	5.27B	4.87B
Gross Profit	1.62B	1.60B	1.26B	1.09B
EBITDA	703.64M	872.47M	573.89M	520.43M
Net Income	473.52M	600.58M	361.80M	305.61M
Balance Sheet
Total Assets	5.07B	4.46B	4.05B	3.47B
Cash, Cash Equivalents and Short-Term Investments	734.15M	622.56M	530.77M	252.65M
Total Debt	108.86M	26.93M	9.07M	42.23M
Total Liabilities	1.81B	1.54B	1.64B	1.33B
Stockholders Equity	3.26B	2.91B	2.41B	2.14B
Cash Flow
Free Cash Flow	169.79M	79.08M	523.51M	272.49M
Operating Cash Flow	371.25M	129.25M	539.02M	288.64M
Investing Cash Flow	-199.09M	9.18M	-434.84M	-78.17M
Financing Cash Flow	-48.60M	-85.68M	-122.87M	-194.49M

Anuh Pharma Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 77.53
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ANUHPHR, the sentiment is Negative. The current price of 77.53 is below the 20-day moving average (MA) of 78.84, below the 50-day MA of 80.36, and below the 200-day MA of 88.57, indicating a bearish trend. The MACD of -0.43 indicates Positive momentum. The RSI at 40.26 is Neutral, neither overbought nor oversold. The STOCH value of 5.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ANUHPHR.

Anuh Pharma Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LINCOLN	74 Outperform	₹9.76B	12.20	―	0.37%	―	―
WANBURY	64 Neutral	₹7.63B	14.33	―	―	8.92%	-5.56%
ANUHPHR	62 Neutral	₹7.72B	19.93	―	1.92%	14.09%	-34.41%
KILITCH	57 Neutral	₹5.85B	19.95	―	―	32.95%	67.39%
KOPRAN	57 Neutral	₹7.21B	40.94	―	1.96%	-6.96%	-66.75%
THEMISMED	54 Neutral	₹9.07B	-33.60	―	0.48%	-18.86%	-150.92%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%